Increased OGA Expression and Activity in Leukocytes from Patients with Diabetes: Correlation with Inflammation Markers

Abstract

O-linked-β-N-Acetylglucosaminylation (O-GlcNAcylation), a reversible post-translational modification involved in diabetic complications, is regulated by only two enzymes, O-linked N-acetylglucosamine transferase (OGT) and β-N-Acetylglucosaminidase (OGA). Increased OGA expression has been described previously in blood cells from patients with diabetes and was interpreted as an adaptative response to hyperglycemia-induced O-GlcNAcylation. OGA expression was thus proposed to have potential utility as a diagnostic marker. The present work was undertaken to determine whether determination of OGA enzymatic activity in blood cells could constitute a more rapidly accessible marker than OGA expression level measurements.

Blood samples were obtained from patients with type 2 diabetes from the Department of Diabetology of the Cochin Hospital and healthy volunteers from the French blood Agency. OGA enzymatic activity and OGA mRNA expression levels were evaluated in leucocytes from patients with type 2 diabetes and from healthy donors.

OGA activity was higher in leucocytes from patients with diabetes compared to control individuals. Surprisingly, OGA activity was not correlated hyperglycaemia markers (blood glucose, fructosamine, HbA_1c) but was positively correlated with the inflammatory marker C-reactive protein. OGA mRNA levels were also increased in leucocytes from patients with diabetes and were correlated with mRNA coding for two pro-inflammatory proteins, TNFα and TxNIP.

Therefore, OGA activity in leucocytes might be a more easily accessible biomarker than OGA expression levels. However, changes in OGA activity observed in patients with type 2 diabetes may reflect the inflammatory rather than the glycaemic status of these patients.

Key words

O-GlcNAcylation - O-linked N-acetylglucosaminidase - O-linked N-acetylglucosamine transferase - hyperglycaemia - Diabetic complications - biomarkers

• References

• 1 Issad T, Kuo M. O-GlcNAc modification of transcription factors, glucose sensing and glucotoxicity. Trends Endocrinol Metab 2008; 19: 380-389
• 2 Issad T, Masson E, Pagesy P. O-GlcNAc modification, insulin signaling and diabetic complications. Diabetes Metab 2010; 36: 423-435
• 3 Lehman DM, Fu DJ, Freeman AB. et al. A single nucleotide polymorphism in MGEA5 encoding O-GlcNAc-selective N-acetyl-beta-D glucosaminidase is associated with type 2 diabetes in Mexican Americans. Diabetes 2005; 54: 1214-1221
• 4 Wang Z, Park K, Comer F. et al. Site-specific GlcNAcylation of human erythrocyte proteins: Potential biomarker(s) for diabetes. Diabetes 2009; 58: 309-317
• 5 Park K, Saudek CD, Hart GW. Increased expression of beta-N-acetylglucosaminidase in erythrocytes from individuals with pre-diabetes and diabetes. Diabetes 2010; 59: 1845-1850
• 6 Springhorn C, Matsha TE, Erasmus RT. et al. Exploring leukocyte O-GlcNAcylation as a novel diagnostic tool for the earlier detection of type 2 diabetes mellitus. J.Clin.Endocrinol.Metab. 2012; 97: 4640-4649
• 7 Kim EJ, Kang DO, Love DC. et al. Enzymatic characterization of O-GlcNAcase isoforms using a fluorogenic GlcNAc substrate. Carbohydr Res 2006; 341: 971-982
• 8 Groussaud D, Khair M, Tollenaere AI. et al. Hijacking of the O-GlcNAcZYME complex by the HTLV-1 Tax oncoprotein facilitates viral transcription. PLoS Pathog 2017; 13: e1006518
• 9 Strobel A, Siquier K, Zilberfarb V. et al. Effect of thiazolidinediones on expression of UCP2 and adipocyte markers in human PAZ6 adipocytes. Diabetologia 1999; 42: 527-533
• 10 Pierre-Eugene C, Pagesy P, Nguyen TT. et al. Effect of insulin analogues on Insulin/IGF1 hybrid receptors: Increased activation by glargine but not by its metabolites M1 and M2. PLoS One 2012; 7: e41992
• 11 Zhou R, Tardivel A, Thorens B. et al. Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nature immunology 2010; 11: 136-140
• 12 Chen J, Saxena G, Mungrue IN. et al. Thioredoxin-interacting protein: A critical link between glucose toxicity and beta-cell apoptosis. Diabetes 2008; 57: 938-944
• 13 Schroder K, Zhou R, Tschopp J. The NLRP3 inflammasome: A sensor for metabolic danger?. Science 2010; 327: 296-300
• 14 Martel MA, Wyllie DJ, Hardingham GE. In developing hippocampal neurons, NR2B-containing N-methyl-D-aspartate receptors (NMDARs) can mediate signaling to neuronal survival and synaptic potentiation, as well as neuronal death. Neuroscience 2009; 158: 334-343
• 15 Li X, Rong Y, Zhang M. et al. Up-regulation of thioredoxin interacting protein (Txnip) by p38 MAPK and FOXO1 contributes to the impaired thioredoxin activity and increased ROS in glucose-treated endothelial cells. Biochem Biophys Res Commun 2009; 381: 660-665
• 16 Cha-Molstad H, Saxena G, Chen J. et al. Glucose-stimulated expression of Txnip is mediated by carbohydrate response element-binding protein, p300, and histone H4 acetylation in pancreatic beta cells. J Biol Chem 2009; 284: 16898-16905
• 17 MarPeterson CW, Ayer DE. An extended Myc network contributes to glucose homeostasis in cancer and diabetes. Front Biosci (Landmark Ed) 2011; 16: 2206-2223
• 18 Kibbe C, Chen J, Xu G. et al. FOXO1 competes with carbohydrate response element-binding protein (ChREBP) and inhibits thioredoxin-interacting protein (TXNIP) transcription in pancreatic beta cells. J Biol Chem 2013; 288: 23194-23202
• 19 Li X, Kover KL, Heruth DP. et al. New insight into Metformin action: Regulation of ChREBP and FoXO1 activities in endothelial cells. Mol Endocrinol 2015; ME20151090
• 20 Kuo M, Zilberfarb V, Gangneux N. et al. O-glycosylation of FoxO1 increases its transcriptional activity towards the glucose 6-phosphatase gene. FEBS Lett 2008; 582: 829-834
• 21 Fardini Y, Masson E, Boudah O. et al. O-GlcNAcylation of FoxO1 in pancreatic beta cells promotes Akt inhibition through an IGFBP1-mediated autocrine mechanism. Faseb J 2014; 28: 1010-1021
• 22 Guinez C, Filhoulaud G, Rayah-Benhamed F. et al. O-GlcNAcylation increases ChREBP protein content and transcriptional activity in the liver. Diabetes 2011; 60: 1399-1413
• 23 Baudoin L, Issad T. O-GlcNAcylation and Inflammation: A Vast Territory to Explore. Front Endocrinol (Lausanne) 2015; 5: 235
• 24 Slawson C, Zachara NE, Vosseller K. et al. Perturbations in O-linked beta-N-acetylglucosamine protein modification cause severe defects in mitotic progression and cytokinesis. J Biol Chem 2005; 280: 32944-32956
• 25 Kazemi Z, Chang H, Haserodt S. et al. O-linked beta-N-acetylglucosamine (O-GlcNAc) regulates stress-induced heat shock protein expression in a GSK-3beta-dependent manner. J Biol Chem 2010; 285: 39096-39107
• 26 Zhang Z, Tan EP, VandenHull NJ. et al. O-GlcNAcase Expression is Sensitive to Changes in O-GlcNAc Homeostasis. Front Endocrinol (Lausanne) 2014; 5: 206
• 27 Nagel AK, Ball LE. O-GlcNAc transferase and O-GlcNAcase: Achieving target substrate specificity. Amino acids 2014; 46: 2305-2316